With recent successful syntheses of positron-la beled ligands for various neurotransmitter systems, the capability for positron emission tomography (PET) imaging and quantitation of neuroreceptors in humans is becoming a reality. A number of neu rotransmitter systems including dopaminergic (Garnett el aI. , 1983; Wagner et aI. , 1983; Mintun et aI. , 1984; Wong et aI. , 1984; Arnett et aI. , 1985; Barrio et aI. , 1986; Farde et aI. , 1986) , opiate (Frost et aI. , 1985) , and benzodiazepine (Samson et aI. , 1985; Frost et aI. , 1986) systems have been studied with PET. The initial results of these studies have demonstrated the great potential of PET for investi gating chemical mechanisms and regulatory pro cesses of neurotransmission in the intact, func tioning human brain. In addition PET can provide the means to examine and assay the interaction of drugs that modify neurotransmitter functions or processes. This approach provides localized mea surements in the living human brain as opposed to other existing techniques where access to these processes is through examining blood and cerebral spinal fluid, which are at a long "biochemical" dis tance from their sites of action in cerebral tissue.
Several techniques for quantitative in vivo assays of neuroreceptor densities and binding affinities with PET have recently been reported in this journal (Perlmutter et aI. , 1986; Wong et aI. , 1986a,b) and in others (Mintun et aI. , 1984; Farde et aI. , 1986) . Most techniques, at present, are based on a model (Fig. 1 ) that is similar in form to the four-rate constant model (Phelps et aI. , 1979; Huang et aI. , 1980) developed as an extension of the Sokoloff deoxyglucose model (Sokoloff et aI. , 1977) . In this model the ligand is assumed to be de livered via arterial blood flow and transported into tissue by passive diffusion. Usually the extraction fraction of ligand from blood into tissue is small and the rate of transport to tissue is not highly de pendent on blood flow (Phelps et aI. , 1986) . The extracted ligand can then bind either to specific or to nonspecific sites in tissue or back-diffuse to the vasculature. The nonspecific binding is assumed to be reversible and to have fast binding and release rates, so the nonspecific binding sites and the un bound ligand in tissue can be considered to be in a common compartment. The specific binding is sat urable and usually has a slow dissociation rate. Based on this model it can be shown that the ki netics of the radiolabeled ligand in tissue can be de scribed by the following set of differential equa tions:
where Cr and Cb are, respectively, the radioactivity concentrations of free (including nonspecific binding) and specifically bound labeled ligand in tissue; C p is that of the labeled ligand in plasma; B m ax is the receptor density; ka and k d are, respec tively, the association and dissociation constants of ligand and receptor; SA is the specific activity of the labeled ligand; f2 is the fraction of ligand in the free and nonspecific binding compartment (Cr) that is free to bind to specific receptors (Mintun et al. , 1984; Perlmutter et al. , 1986) ; and the kj terms are rate constants for the various transport steps shown in Fig. 1 . If the specific activity of the la beled ligand is high and the total mass of ligand in troduced in tissue is far from reaching the saturable level of the available specific binding sites (i. e. ,
Cb/SA <lS Bmax), then k3 is approximately equal to kaBmaxf2 and the above equation becomes a set of constant -coefficient first -order ordinary differential equations. Based on this model, quantitation of li gand-receptor interactions is circumscribed to the estimation of the values of the model parameters from PET measurements of the radioactivity in tissue. The various techniques used so far for quan titating this information can be grouped into two general categories, i. e. , dynamic and equilibrium approaches.
DYNAMIC APPROACH
Methods with the dynamic approach were used by Wong et al. (1986a,b) , Mintun et al. (1984) , and Perlmutter et al. (1986) . They require measurement of the time courses (kinetics) of the radioactivity in tissue and in blood, just like any other dynamic PET study. The measured kinetics in tissue and blood are subsequently compared with the model predictions to estimate various model parameters (rate constants for transport, binding, and release of ligand). This approach has been used mostly with high specific activity (200-1,000 Ci/mmol) ra diolabeled ligands having high receptor binding af finities (KD = 0.1-1 nM) for dopamine D2-re ceptors. For these radiolabeled ligands the mea sured radioactivity in tissue containing the receptor of interest would increase continuously owing to the accumulation of ligand at the receptor binding sites, while in tissue lacking the receptors, the tissue radioactivity would decrease gradually after the initial maximum. At �40-60 min after tracer administration, the tissue regions with the specific receptors would have a high uptake in contrast to regions void of specific receptors, providing a good visualization of the anatomical distribution of the receptors in the tomographic images. In other words, the presence or absence of the receptors can be detected from the radioactivity distribution in tissue.
Because of their high specific activities, ligands used for the dynamic approach are injected in trace amounts (i. e. , <0.5 nmollkg body weight). This allows the linearized version of the model equation to be used in parameter estimation to extract quan titative results, simplifying the solution of the dif ferential equation. However, it should be noted that the value of k3 in the linearized equation is very sensitive to the mass of ligand introduced because of the high affinity of the ligand and the small number of specific binding sites (in the picomole per-gram range) (Frost, 1982) . Relatively small dif ferences (e .g., 5 nmol/kg) in the amount of injected ligand could result in significant changes in the esti mated value of k3' independently of true physiolog ical variations.
With the dynamic approach the receptor density (Bmax) in tissue cannot be separated from the asso ciation constant of receptor binding (ka). Only the combined term Bmaxkaf2' or Bmaxf21KD if k31k4 is calculated, can be estimated, where KD is the equilibrium dissociation constant of the recep tor ligand binding. The value of f2 can usually be obtained from in vitro studies or estimated from the kinetics in tissue regions lacking specific receptors (Mintun et al. , 1984; Perlmutter et al. , 1986) . With the value of f2 known, the product of ka and Bmax , which has been referred to as a "binding potential" by Mintun et al. (1984) , can be obtained.
For estimation of the model parameters from the measured kinetics, two techniques have been em ployed. The more general one is nonlinear regres sion [the "explicit method" referred to by Perl mutter et al. (1986) ], which gives the set of param eter values that minimizes the deviation between the measured kinetics and the model prediction. The other technique is the normalized graphical method (Patlak et al. , 1983; Gjedde et al. , 1985) [the "ratio method" referred to by Perlmutter et al. (1986) ], which transforms the coordinates of the tissue time-activity curve to normalized tissue ac tivity (i. e. , tissue activity divided by plasma ac tivity) versus normalized time (i. e. , J(plasma ac tivity) dt divided by plasma activity). The latter is just a particular way of representing the tissue time-activity curve to aid in the estimation of cer tain parameters in the general model shown in Fig.   1 . For example, when k4 = 0, the tissue kinetics on a normalized graphical will approach a straight line with a slope of klk3/(k2 + k3) and an intercept at the y-axis of klk2/(k2 + k3) 2 . Therefore, the normalized graphical plot is a very simple way to show whether k4 is negligible or not, and, if it is negli gible, to show the magnitude of klk3/(k2 + k3)' For example, the linearity of the striatum-to-cere bellum ratio for 3-N-[11C]methylspiperone first ob served by Wagner et al. (1983) and Wong et al. (1984) indicates that k4 is small for the tracer. The individual values of the transport rate constants kl and k2' however, are not directly provided by the normalized graphical plot. Using the other param eter estimation technique (the "explicit method" ), Mintun et al. (1984) and Perlmutter et al. (1986) have obtained estimates of i2' Bmaxka, and kd for
[18F]spiperone (specific activity of 10-30 Ci/mmol) binding in the striatum of the baboon. The product
Bmaxka was also shown to respond as expected to pretreatment with various mass doses (0.1-0.52 mg/kg) of unlabeled spiperone (Perlmutter et aI. , 1986) .
The dynamic approach provides the most infor mation one can possibly obtain from the kinetic measurements. However, it is very sensitive to the exact model configuration assumed and to mea surement errors in the time-activity curves in tissue and blood. Correction of the arterial radioac tivity for labeled metabolites of the injected tracer is necessary. Wong et al. (l986a) in their studies with 3-N-[11C]methylspiperone have devised a technique to estimate the fraction of metabolites in plasma from the time-activity curves in a refer ence tissue region (cerebellum) free of specific bindings. This approach is based on the assumption that the cerebellum-to-plasma ratio of the labeled ligand approaches exponentially to a constant equi librium value. Further validation of the assump tions is required and must be examined specifically for each ligand.
An alternative method to circumvent the metabo lite correction is to regard the kinetics in the refer ence tissue region as a close approximation for the nonspecifically bound and free ligand in the tissue region of interest, eliminating the need to measure the arterial input function. This requires the kinetic properties of the ligand transport and nonspecific binding of the reference region to be equivalent to those in the regions that: contain specific binding sites and that no radio labeled metabolites enter the brain. The issue of whether any labeled metabolic products cross the blood-brain barrier (BBB) is a confounding problem. Usually metabolic products of hydrophobic ligands have increased polarity and limited diffusion through the BBB may be ex-pected, although this is not always the case and must be determined experimentally. If metabolic products have been shown not to cross the BBB, the tissue time-activity curve in nonspecific binding regions provides an internally normalized input function that is "filtered" of the metabolic products (assuming the vascular contribution to tissue activity is negligible). To use this filtered input function, the rate of specific binding (k3) of the ligand also needs to be small relative to the transport rate back to the vascular space (k2), be cause, according to the general model of Fig. 1 , the ligand distribution volume (i. e. , tissue-to-plasma ratio of labeled ligand concentrations) is k/(k2 + k3) in a region with specific binding (assuming negli gible k4), while it is k/k2 for a region devoid of spe cific binding. The two are equivalent only when k3 � k2·
If all the above assumptions hold, then the tissue time-activity curve in regions devoid of the spe cific binding would represent that of the nonspecifi cally bound and free ligand (i. e. , Cf in the model of Fig. 1 ) in regions with specific binding. In other words, the model can be further simplified because Cf can be obtained directly without the arterial input function. In this case the rate constant of spe cific binding (k3) of the ligand in a region of interest can be more easily estimated. For example, using the normalized graphical method with the kinetics in the reference tissue region replacing the plasma time-activity curve, the slope of the data will be the value of k3 (assuming k4 is negligible). In a more recent article, however, Wong et al. (1986a) pro pose that there is a significant amount of secondary non-dopamine D2-binding sites for 3-N-[11C]meth ylspiperone in striata of humans that appear absent in cerebellum. If this is the case, the assumption for using cerebellum directly as a reference region does not hold for 3-N-[1 l C]methylspiperone. There fore, the approach needs careful and extensive vali dation. Wong et al. (1986b) have recently applied the dy namic approach to normal human subjects to ex amine changes in the k3 value of 3-N-[ ll C]methyl spiperone with an oral dose of haloperidol (5-7.5 mg). From the amount of changes in k3 and an as sumed value of kd for haloperidol, the values of Bmax and the inhibition constant of haloperidol in caudate were calculated to be 9.2 pmol/g and 1.4 nM, respectively. Although the value of kd chosen for haloperidol in the calculation was rather arbi trary, the work shows an approach of employing a competitive ligand of common use that has a weaker affinity to help estimate the value of Bmax.
EQUILIBRIUM APPROACH
The equilibrium approach is an in vivo analogy of the in vitro ligand assay techniques used for deter mination of receptor density and dissociation con stants . Methods using this ap proach are designed to measure the fraction of li gand bound to receptors under various tissue concentrations of the unbound ligand. Farde et al. (1986) have used this approach with [I l CJraclopride to measure dopamine D2-receptor density and Ko in the striatum of humans. With this approach, mul tiple PET determinations at different specific activi ties of the labeled ligand are performed to measure the fractions of bound ligand under various levels of unbound ligand concentrations in tissue. It is as sumed with this approach that the binding and re lease of ligands at specific binding sites are in equi librium during the time of measurement and the concentration of the unbound ligand in tissue can be estimated (either from a reference tissue region or indirectly from the ligand concentration in blood). Assumptions and restrictions for the use of reference tissue regions are similar to those dis cussed above for the dynamic approach.
The equilibrium approach is suitable for labeled ligands that have relatively fast release rates from the receptor of interest so that an equilibrium (a secular equilibrium or at least an approximation of it) can be established within a reasonably short time for PET measurements. Time to reach equilibrium is also related to the time of approaching a constant level for the ligand concentration in plasma. This implies that the metabolism and clearance of the li gand in the body during the experiment should be minimal. Slow ligand clearance would also help maintain a sufficiently high radioactivity concentra tion in the brain during equilibrium for PET mea surements. The binding of [IICJraclopride to dopa mine D2-receptors seems to satisfy most of these requirements, while labeled spiperone and some of its analogues do not have desirable properties for this approach. Fast scanning capability of the PET scanner is not needed for the equilibrium methods.
A significant advantage of the equilibrium ap proach is that one can estimate the individual values of both Bmax and Ko (assuming f2 is known or measured independently). The semigraphical techniques such as the Scatchard and the Hill plots that are employed for in vitro ligand assays can be used directly for in vivo estimations. The reliability and limitation of these estimation techniques for in vitro ligand assays are also applicable to the case of PET studies. In addition how close the equilibrium state is approximated during the measurement time J Cereb Blood Flow Metab, Vol. 6. No.5, 1986 and how accurate the unbound ligand concentration is estimated will have a direct effect on the reli ability and accuracy of the results from the equilib rium approach (Hartley and Seeman, 1978) . How ever, initial studies by Farde et al. (1986) using this approach have demonstrated its feasibility. By as suming anf2 value of 0.8-0.9, they have estimated Bmax to be 14.4 pmoIlg and Ko to be 3.8 nM for ra clopride binding to the dopamine D2-receptors in normal human subjects.
A potential advantage of the use of more weakly bound ligands in the equilibrium approach is that the binding may be sensitive to the presence of en dogenous neurotransmitter binding to the same sat urable receptor binding sites. Measurements with these ligands potentially would be more responsive indicators of changes in neurotransmission and be havior. However, this has not yet been demon strated.
NEW POTENTIAL APPROACHES
There are many potential approaches that can combine the advantages of those discussed above. For example, in equilibrium studies, if the kinetics of reaching the equilibrium state were measured, information about the transport and receptor binding of the radiolabeled ligand could be obtained in a manner analogous to that used in dynamic ap proach methods, except that the nonlinear form of the differential equation (Eq. 1) should be retained for low specific activity studies. In fact, the nonlin earity allows the saturation parameters (i.e., Bmax and kJ of the receptor binding to be obtained from a single study. With a dose of appropriately se lected specific activity, the ligand concentration in tissue can vary from high levels (near-saturation of receptor binding) at early times to low levels (non saturation of binding) near the end of the study owing to clearance of the ligand from tissue to blood. Basically the binding and release rates of li gand to receptors under various ligand concentra tions can be examined under the conditions of this dynamic environment. That is, multiple repeated studies with various specific activities are not needed with this approach. A necessary assump tion for this method is that binding and dissociation rates between ligand and receptor are sufficiently fast that binding saturation does not mask the non saturable binding kinetics.
A different potential approach for estimating the individual values of Bmax and ka (or Ko) employs labeled ligands of high receptor binding affinity and slow release rate. The approach involves the use of multiple dynamic studies of various specific activi ties, in analogy with the conventional equilibrium approach. Again, except for high specific activity experiments in which only a negligible proportion of receptors are occupied, the differential equation (Eq. 1) cannot be linearized and its solution is more complex. However, for these labeled ligands of high receptor binding affinity, most specific binding occurs quickly and the plasma concentration of the labeled ligand drops rapidly to a low level after bolus injection. Thus, a constant value of k3 could be approximated shortly after the administration of the tracer, and the differential equation (Eq. 1) would still have constant coefficients. However, the values of k3 would be different for different dose conditions (i. e. , specific activities), because of the k3 dependency on Cb/SA (Eq. I). This dose depen dency of the k3 value could then be used to provide estimates of the individual values of Bmax and ka (Eq. I). Figure 2 shows the results of a double-injection approach with a nemistrina monkey and 3-(2'-[18F]fluoroethyl)spiperone (FESP), a recently synthesized radiolabeled spiperone analogue (Barrio et aI. , 1986) . The time-activity curves re corded with PET are shown for the striatum (rich in dopamine receptors) (circles) and cerebellum (void of dopamine receptors) (triangles) regions. At time zero a 4-mCi dose of FESP of high specific activity (650 Ci/mmol) was injected. A second dose (2 mCi) of FESP of lower specific activity (16 Ci/mmol) was injected at 95 min (indicated by arrow in Fig.  2) . Owing to the saturable binding property of FESP to dopamine D2-receptors, the radioactivity in the striata after the second injection was cleared faster than after the first injection. When these data were plotted in terms of the normalized tissue ac tivity and normalized time with the cerebellum as the reference region (i. e. , normalized graphical plot with the time-activity curve in the cerebellum re gion as the input function), the slope (an estimate of k3) of the data after the second injection is 50% lower than after the first injection. This change in k3 corresponded to � 50% saturation of the re ceptors with the second injection. Values of Bmax and ka were estimated to be 11 pmol/g tissue and 0. 05/min-nM, respectively. Performing double in jections consecutively allows the estimate of the in dividual ligand-receptor binding parameters in a single setting. In addition it avoids the patient repositioning problem associated with multiple studies and thus improves the reliability of the re sulting estimates.
OTHER GENERAL QUESTIONS AND ISSUES
The approaches discussed above provide the ca pability to quantitate ligand assays with PET. How ever, the selection of an approach depends very much on the characteristics of the labeled ligand and on the neuroreceptor system being studied. In addition to the characteristics discussed above, the pharmacological effects of the ligand should be well understood and carefully considered in planning neuroreceptor studies with PET. All of the ap proaches proposed require larger-than-tracer amounts of the labeled ligand or a competitive li gand to be administered at some point in the study protocol, if the values of B m ax, ka' and KD are to be estimated individually. This could be a prohibitive factor for ligands that are very potent and/or that have long-lasting pharmacological effects .
The validation of a PET method for a neurore ceptor assay is usually done by comparing the re sults with those obtained from in vitro binding ex periments. Good agreement of results is usually considered to be an indication of the validity of the method. However, caution must be exercised in these comparisons. Binding discrepancies between in vitro and in vivo conditions have been observed with certain ligands (Frost, 1982) . In in vitro re ceptor binding experiments, the concentration of the unbound ligand is uniform, while the uniformity of the unbound ligand concentration in tissue in vivo is less likely to be maintained owing to a multi plicity of factors such as the fast binding-rebinding phenomenon in the synaptic zone and diffusional re strictions (Frost, 1982) . This may result in signifi-cant tissue subcompartmentalization of the injected ligands. Therefore, the measured KD values, which are dependent on the estimated concentration of unbound ligands, may not be the same between the in vitro and the in vivo studies, owing to differences in factors relating to the functional and structural integrity of the neurotransmitter system. Moreover, the binding step (k3) in the compartmental model ( Fig. 1 ) could certainly be more complicated than the simple binding between ligand and receptor. For example, dopamine-mediated receptor internal ization with ligand sequestration may be respon sible for the slow clearance rate of spiperone in vivo (�12 h vs. 2-10 min in vitro) (Chugani et aI. , 1985) . This mechanism appears to be lost in in vitro preparations due to a lack of an intact, functioning synaptic system (Chugani et aI. , 1985) .
The ligand binding characteristics of receptor systems have been shown to have large species-to species diff erences in both KD and Bmax values (Lua beya et aI. , 1986). Therefore, the exact agreement of results obtained with a PET method with those from in vitro experiments or from other species is neither a necessary nor a sufficient condition for in ferring the validity of a technique. Confirmation of model predictions of compartmental concentrations as a function of time by chemical assay and correct response to interventions with known changes in the rates or concentrations of synaptic processes are probably better criteria. This requires a combi nation of kinetic, physiologic, pharmacologic, and biochemical tracer assay approaches to structure and validate the methods and procedures.
Interpretation of quantitative results from neu roreceptor assay with PET in terms of physiolog ical information also needs to be done with care.
For example, the measured Bmax may represent a significant number of intracellular receptor sites for ligand binding that are not associated with surface membrane receptors in the synaptic junction. Also, owing to the finite spatial resolution of PET scanners (>5 mm full width at half-maximum), the measurements (either dynamic or static) obtained from PET will represent in some brain areas an ad mixture of heterogeneous tissues (Mazziotta et aI. , 1981) . Since the estimates of Bma x and ka (or KD) do not, in general, have a linear relationship with re spect to the measurements, biases (sy stematic errors) in the estimates can be expected (Huang et aI. , 1986) . The amount of this sy stematic error is also expected to be related to the method used for estimation and should be evaluated carefully.
In addition to the study of postsynaptic re ceptors, access to the biochemical processes of the presynaptic system would provide further noninva-J Cereb Blood FlolV Me/ab, Vol. 6, No. 5, 1986 sive evaluation of the underlying mechanisms and regulation of neurotransmission. For example, using 6-[ISF]L-fluorodopa (Garnett et aI. , 1983; Martin et aI. , 1985) , its radiolabeled enantiomer, and analogues, one can selectively probe the neu tral amino acid transport, and storage, release, reuptake, and metabolism of dopamine. The selec tion of appropriate radiolabeled fluorodopa deriva tives would also permit isolation of neurotrans mitter processes that minimize interference of other related metabolic events, such as those cata lyzed by catecholamine-O-methyltransferase and monoamine oxidase. Manipulation of the system using inhibitors of dopamine storage, monoamine oxidase inhibitors, or neuroleptic blockade would illustrate various aspects of neuroreceptor dy namics and neurotransmitter synthesis and regula tion. Understanding of the various processes at the molecular or cellular level will provide not only de tailed biochemical information, but also a rigorous basis for the formulation of a model configuration for correctly interpreting the in vivo results.
The probing of the neurotransmitter systems in vivo with PET is still at a very early stage, although initial feasibility studies are very encouraging. Ob viously further investigation and improvements are required. The ability to examine both the neuro transmitter and the neuroreceptor systems in vivo will surely increase our understanding of specific local neurological function of the human brain. In addition coordinated studies from many perspec tives (such as anatomical, electrophysiological, biochemical, pharmacological, developmental, and behavioral) and with many model systems (ranging from isolated enzymes, cells, and tissues to intact functioning organisms) are needed to understand the neurotransmission processes. A successful and rewarding partnership between in vivo autoradiog raphy (in animals) and PET has already been devel oped as exemplified by the measurements of blood flow, glucose utilization, and protein synthesis (Phelps et aI. , 1985) . This is only the beginning of a long synergism among different methodologies and between basic and clinical sciences to address the common scientific question of how the brain func tions.
